Talphera Inc美股招股说明书(2025-12-02版)

Up to 1,023,890 Shares of Common Stock Up to 1,706,484 Shares of Common Stock Issuable Upon Exercise of Pre-Funded Warrants This prospectus relates to the proposed resale from time to time by the selling stockholders of up to 1,023,890 shares ofcommon stock and 1,706,484 shares of common stock issuable upon exercise of pre-funded warrants. The selling stockholders purchased the common stock and pre-funded warrants from us pursuant to securities purchaseagreements, dated March 31, 2025. We are not selling any of our common stock pursuant to this prospectus, and we will not receive any proceeds from the sale ofour common stock offered by this prospectus by the selling stockholders. The selling stockholders may offer and sell or otherwise dispose of the shares of our common stock described in thisprospectus from time to time through public or private transactions at prevailing market prices, at prices related to prevailingmarket prices or at privately negotiated prices. The selling stockholders will bear all underwriting fees, commissions and discounts,if any, attributable to the sales of shares and any transfer taxes. We will bear all other costs, expenses and fees in connection with Our common stock is listed on The Nasdaq Capital Market under the trading symbol “TLPH.” On November 28, 2025, the last Investing in our common stock involves a high degree of risk. You should review carefully the risks and uncertaintiesdescribed under the heading“Risk Factors”on page 3 of this prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved ofthese securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal The date of this prospectus isDecember 1, 2025. ABOUT THIS PROSPECTUS Neither we nor the selling stockholders have authorized anyone to provide you with any information other than that containedin, or incorporated by reference into, this prospectus. We take no responsibility for, and can provide no assurance as to thereliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of our commonstock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should not assume that the This prospectus contains summaries of certain provisions contained in some of the documents described herein, but referenceis made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actualdocuments. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference Unless the context indicates otherwise, as used in this prospectus, the terms “Talphera,” “Talphera, Inc.,” “we,” “us” and “our”refer to Talphera, Inc., a Delaware corporation. PROSPECTUS SUMMARY This summary highlights selected information contained elsewhere in this prospectus or incorporated by reference inthis prospectus, and does not contain all of the information that you need to consider in making your investment decision.You should carefully read the entire prospectus, including the risks of investing in our securities discussed under theheading“Risk Factors”contained in this prospectus and under similar headings in the other documents that are Talphera, Inc. Overview We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapiesfor use in medically supervised settings. Our product development portfolio features Niyad (a regional anticoagulant for thedialysis circuit), LTX-608 (a nafamostat formulation for direct IV infusion) that we intend to develop for one or more of thefollowing indications: disseminated intravascular coagulation, or DIC, acute respiratory distress syndrome, or ARDS, acutepancreatitis, or as an anti-viral treatment, and two ready-to-use pre-filled syringe product candidates (Fedsyra and Private Placement of Common Stock and Pre-Funded Warrants On March 31, 2025, we entered into securities purchase agreements with the selling stockholders, or the 2025 PrivatePlacement. In October 2025, certain purchasers waived on behalf of themselves only, the closing conditions and certain ●1,023,890 shares of common stock; and ●pre-funded warrants to purchase up to an aggregate of 1,706,484 shares of common stock at an exercise price of$0.001 per share. The pre-funded warrants are exercisable immediately and have an unlimited term. The purchase price per share and per pre-funded warrant was $0.586 and $0.585, respectively, for aggregate grossproceeds of approximately $1.6 million, before deducting expenses payable by us. The selling stockholders have exercised their full purchase allocations under the 2025 Private Placement, including allshares of common stock an